Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7094960 | 0.68 | KDM4E (0.37) | KAT2BKDM4ESMN1; SMN2HSD17B10ALOX15 | |
| SCHEMBL5163732 | 0.65 | GSK3A (0.66) | KAT2BKDM4ESMN1; SMN2ALDH1A1PPARG | |
| SCHEMBL7413865 | 0.64 | MAPT (0.34) | KAT2BKDM4ESMN1; SMN2HSD17B10ALOX15 | |
| SCHEMBL6422039 | 0.63 | GSK3A (0.45) | KAT2BKDM4ESMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL11844901 | 0.62 | KMT2A (0.39) | KAT2BKDM4ESMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL6350869 | 0.61 | KAT2B (0.38) | KAT2BKDM4ESMN1; SMN2HSD17B10ALOX15 | |
| SCHEMBL6350872 | 0.61 | KAT2B (0.38) | KAT2BKDM4ESMN1; SMN2HSD17B10ALOX15 | |
| SCHEMBL24703554 | 0.61 | KDM4E (0.57) | KAT2BKDM4ESMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL2138759 | 0.61 | — | — | |
| SCHEMBL22004951 | 0.60 | NFE2L2 (0.45) | KAT2BKDM4ESMN1; SMN2HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605978-A2 | THERAPEUTIC COMPOSITIONS | Alnylam Pharmaceuticals Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004080406-A2 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2004-09-23 | — | — | WO | disclosed |